Saturday 17 October 2026 Export CSTL’s income statement to Excel — free account

Castle Biosciences, Inc.

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%

Follow CSTL

Alert me

Market cap: $1.0B
P/E: 0.0×
Fwd P/E: −15.2×
Dividend yield: —
F-score: 3/9
Altman Z: 6.70
Beneish M: −3.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.65

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	9	8	2	1	8	2	2	3	6	9	5	3

Insider Ownership 1.51%

Capital & Financial Ratios $m

Market Cap 1,030.00

Revenue 357.28

Net Income (19.41)

Free Cash Flow (0.45)

Net Debt (256.47)

Current Ratio 6.04

Debt/Equity 0.02

P/E ratio 0.00

Fwd P/E (15.20)

P/S ratio 2.72

P/B ratio 2.07

Past 5Y EPS Growth —

This Y EPS Growth (51.54%)

Next Y EPS Growth 27.39%

Next Y revenue growth 8.42%

Next 5Y EPS Growth 24.66%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 34.87%

10-year low 10-year high

P/B against its own 10 years 57.22%

10-year low 10-year high

EV/Sales against its own 10 years 41.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	243	293	300	267
Receivables	38	51	43	48
Inventory	8	8	10	11
Other	—	—	—	—
	296	360	361	341

	2023	2024	2025	Q'26
Payables	10	7	19	10
ST’ Debt	—	0	0	3
Other	—	—	1	2
	48	49	69	57

Compound Annual Growth %

	10y	5y	3y
Sales	—	40.60%	35.94%
Cash Flow	—	45.51%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	2.52%	5.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	84	104	—	—	—
’25	88	86	83	87	344
’24	73	87	86	86	332
’23	42	50	61	66	220
’22	27	35	37	38	137
’21	23	23	23	25	94
’20	17	13	15	17	63

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	15	—	—	—
’25	(6)	21	23	27	64
’24	(7)	24	23	24	65
’23	(25)	(4)	5	19	(6)
’22	(21)	(9)	(5)	(6)	(42)
’21	(4)	(6)	(6)	(3)	(19)
’20	0	14	(3)	0	10

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(35)	7	—	—	—
’25	(11)	12	8	20	28
’24	(16)	19	17	17	37
’23	(29)	(8)	3	15	(19)
’22	(22)	(10)	(7)	(8)	(47)
’21	(4)	(7)	(7)	(4)	(22)
’20	(1)	12	(5)	(1)	5

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.49)	(0.07)	—	—	—
’25	(0.90)	0.15	(0.02)	(0.08)	(0.83)
’24	(0.09)	0.31	0.08	0.32	0.62
’23	(1.10)	(0.70)	(0.26)	(0.10)	(2.14)
’22	(0.97)	(0.06)	(0.77)	(0.78)	(2.58)
’21	(0.17)	(0.35)	(0.47)	(0.25)	(1.24)
’20	0.03	(0.08)	(0.23)	(0.23)	(0.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	15.26	21.01	37.99	15.58	9.26	16.97	14.59	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	39.77	78.40	107.69	48.40	29.59	35.84	42.18
People
People	Employees	—	—	96	135	201	345	543	610	761	883
	Revenue/emp, $m	—	0.00	0.24	0.38	0.31	0.27	0.25	0.36	0.44	0.39
Income, $m
Income, $m	Revenue	—	14	23	52	63	94	137	220	332	344
	Gross margin, %	—	63.33	76.75	85.91	84.54	83.18	76.64	79.53	81.87	79.37
	EBT	—	(12)	(6)	5	(10)	(40)	(69)	(57)	22	(30)
	EBT margin, %	—	(89.86)	(27.90)	10.31	(16.28)	(42.53)	(50.28)	(26.10)	6.49	(8.57)
	Net income	—	0	(6)	5	(10)	(31)	(67)	(57)	18	(24)
	Depreciation	—	0	1	2	1	3	9	7	9	37
Per share, $
Per share, $	Revenue	—	0.83	11.95	6.04	3.31	3.74	5.26	8.20	11.96	11.88
	Earnings	—	(0.92)	(3.34)	0.35	(0.54)	(1.24)	(2.58)	(2.14)	0.66	(0.83)
	Cash flow	—	(0.73)	(6.45)	0.82	0.52	(0.76)	(1.60)	(0.21)	2.34	2.22
	Capex	—	0.00	(0.15)	(0.11)	(0.25)	(0.14)	(0.21)	(0.51)	(1.02)	(1.24)
	Free cash flow	—	(0.73)	(6.60)	0.71	0.27	(0.89)	(1.81)	(0.72)	1.32	0.98
	Book value	—	(0.95)	(29.68)	9.92	21.96	16.38	15.32	14.60	16.41	16.24
	Shares, m	—	17	2	9	19	25	26	27	28	29
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	41.00	0.00
	P/S	—	1.70	1.70	5.69	20.29	11.45	4.33	2.68	2.23	3.28
	P/B	—	0.00	0.00	3.47	3.06	2.62	1.49	1.50	1.62	2.39
	EV/Sales	—	1.96	1.96	4.27	14.11	8.04	2.54	1.64	1.38	2.44
	EV/FCF	—	(13.90)	(13.90)	36.41	172.70	(33.67)	(7.39)	(18.72)	12.51	29.55
Cash, $m
Cash, $m	Operating cash flow	—	(12)	(12)	7	10	(19)	(42)	(6)	65	64
	Capex	—	0	0	(1)	(5)	(3)	(5)	(14)	(28)	(36)
	Free cash flow	—	(12)	(13)	6	5	(22)	(47)	(19)	37	28
Balance, $m
Balance, $m	Working capital	—	1	11	101	409	329	256	248	311	292
	Total debt	—	20	25	25	—	8	13	—	10	10
	Net debt	—	19	20	(74)	(410)	(322)	(245)	(243)	(283)	(289)
	Shareholders’ equity	—	(16)	(57)	85	416	412	399	391	456	471
Returns, %
Returns, %	ROA	—	(95.00)	(90.72)	4.21	(3.68)	(6.94)	(14.76)	(12.76)	3.71	(4.35)
	ROIC	—	0.00	0.00	40.21	(70.02)	(27.78)	(29.60)	(28.67)	3.13	(14.72)
	ROE	—	28.65	19.02	20.95	(4.11)	(7.56)	(16.56)	(14.54)	4.31	(5.21)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)	Compare
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)
FLGT Fulgent Genetics, Inc.	$587.2M	— (loss-making)	— (loss-making)	+4.38% (above 0%: growing)	n/m	+25.36% (above 0%: growing)	30.07%	(42.25%)	Compare
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
Median of peers	$1.9B	—	—	+11.33%	—	+29.16%	57.76%	(10.05%)

All 52 Diagnostics & Research stocks →

Castle Biosciences, Inc. (CSTL) key facts

Strength: Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
Castle Biosciences, Inc. (CSTL) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CSTL traded at $31.96, a market capitalization of $1.0 billion.
Return on equity was −5.21% and debt-to-equity 0.02.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 6.70 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.